` CODX (Co-Diagnostics Inc) vs S&P 500 Comparison - Alpha Spread

CODX
vs
S&P 500

Over the past 12 months, CODX has underperformed S&P 500, delivering a return of -81% compared to the S&P 500's 9% growth.

Stocks Performance
CODX vs S&P 500

Loading
CODX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CODX vs S&P 500

Loading
CODX
S&P 500
Difference
www.alphaspread.com

Performance By Year
CODX vs S&P 500

Loading
CODX
S&P 500
Add Stock

Competitors Performance
Co-Diagnostics Inc vs Peers

Co-Diagnostics Inc
Glance View

Market Cap
9.4m USD
Industry
Health Care

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

CODX Intrinsic Value
Not Available
Back to Top